SpectaScience Inc. (OTCBB: SCIE), a developer of light-based diagnostic technology for cancer identification, similar to companies like Verisante Technology Inc. (CVE: VRS) and MELA Sciences Inc. (NASDAQ: MELA), recently completed its WavSTAT4 installation and training under its distribution agreement with PENTAX in Europe.

Investors are hoping that the move paves the way for near-term revenues now that the units are in place and the staff is trained. PENTAX is the third largest competitor in the gastrointestinal endoscopic market with a 17.4% market share.

SpectraScience, Inc. (SCIE), a San Diego-based medical device company, today announced it has successfully completed installation and training for the WavSTAT4 Optical Biopsy System with PENTAX Europe at multiple customer sites, including the United Kingdom (London), France (Paris and Nantes), The Netherlands (Maastricht and Breda), and Germany (Erlangen).

The training involved basic and advanced operations, followed by troubleshooting skills, repair of induced failures, and demonstrations for key physicians. The WavSTAT units also met certain performance measures and passed electrical safety tests prior to being accepted into the hospital systems.

“The initial order delivery and product training with PENTAX were completed on schedule, and the customer technicians have been very pleased with the ease of operation and serviceability of the WavSTAT units,” said Michael Oliver, SpectraScience’s Chief Executive Officer. “Likewise, we have been impressed with the qualifications, experience and capability of the PENTAX technicians assigned to operate and maintain our systems. Following the installation and training, WavSTAT4 units were placed in procedure rooms at several hospitals. We are pleased with the progress made in the two months since signing our distribution agreement with PENTAX, and look forward to filling additional orders this quarter.”

About SpectraScience, Inc.

SpectraScience is a San Diego-based medical device company that designs, develops, manufactures and markets light-based analysis systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically diagnose tissue and provide the physician with an immediate analysis. With approval for sale under the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use.